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Amyotrophic lateral sclerosis transcriptomics
reveals immunological effects of low-dose
interleukin-2
Ilaria Giovannelli,1 Nadhim Bayatti,1 Abigail Brown,1 Dennis Wang,1,1 Marius
Mickunas,2William Camu,3 Jean-Luc Veyrune,4 Christine Payan,5,6 Cecilia Garlanda,7,8
Massimo Locati,8,10 Raul Juntas-Morales,3 Nicolas Pageot,3 Andrea Malaspina,11
Ulf Andreasson,12 Carey Suehs,6,13,14 Safa Saker,15 Christophe Masseguin,16 John de Vos,4
Henrik Zetterberg,12,17,18,19 Ammar Al-Chalabi,20,21 P. Nigel Leigh,22 Timothy Tree,2,23
Gilbert Bensimon,5,6,24 Paul R. Heath,1 Pamela J. Shaw1,† and Janine Kirby1,†
†Joint senior authors.
Amyotrophic lateral sclerosis is a fatal neurodegenerative disease causing upper and lower motor neuron loss and currently
no effective disease-modifying treatment is available. A pathological feature of this disease is neuroinflammation, a mech-
anism which involves both CNS-resident and peripheral immune system cells. Regulatory T-cells are immune-suppressive
agents known to be dramatically and progressively decreased in patients with amyotrophic lateral sclerosis. Low-dose
interleukin-2 promotes regulatory T-cell expansion and was proposed as an immune-modulatory strategy for this disease.
A randomized placebo-controlled pilot phase-II clinical trial called Immuno-Modulation in Amyotrophic Lateral Sclerosis
was carried out to test safety and activity of low-dose interleukin-2 in 36 amyotrophic lateral sclerosis patients
(NCT02059759). Participants were randomized to 1MIU, 2MIU-low-dose interleukin-2 or placebo and underwent one in-
jection daily for 5 days every 28 days for three cycles. In this report, we describe the results of microarray gene expression
profiling of trial participants’ leukocyte population. We identified a dose-dependent increase in regulatory T-cell markers
at the end of the treatment period. Longitudinal analysis revealed an alteration and inhibition of inflammatory pathways
occurring promptly at the end of the first treatment cycle. These responses are less pronounced following the end of the
third treatment cycle, although an activation of immune-regulatory pathways, involving regulatory T-cells and T helper 2
cells, was evident only after the last cycle. This indicates a cumulative effect of repeated low-dose interleukin-2 administra-
tion on regulatory T-cells. Our analysis suggested the existence of inter-individual variation amongst trial participants and
we therefore classified patients into low, moderate and high-regulatory T-cell-responders. NanoString profiling revealed
substantial baseline differences between participant immunological transcript expression profiles with the least responsive
patients showing a more inflammatory-prone phenotype at the beginning of the trial. Finally, we identified two genes in
which pre-treatment expression levels correlated with the magnitude of drug responsiveness. Therefore, we proposed a
two-biomarker based regression model able to predict patient regulatory T-cell-response to low-dose interleukin-2. These
findings and the application of this methodology could be particularly relevant for future precision medicine approaches to
treat amyotrophic lateral sclerosis.
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distribution, and reproduction in any medium, provided the original work is properly cited.
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Amyotrophic lateral sclerosis (ALS) is a devastating neurode-
generative disease affecting upper and lower motor neurons,
causing death usually within 3–5 years from the diagnosis.1
Currently, there is no effective disease modifying treatment
available. The only approved drugs are riluzole and edara-
vone. However, these treatments produce only modest effects
on life expectancy and disability progression.2–6
ALS is considered a multifactorial disease, as a series of
mechanisms are implicated in its onset and progression.7–9
Amongst these, neuroinflammation, which involves both
CNS-resident and peripheral immune cells, is currently of
increasing interest.10 Regulatory T-cells (Tregs) represent a
T-cell subset with immune-regulatory properties. They sup-
press excessive inflammatory responses, preventing the es-
tablishment of autoimmune disorders.11 Tregs were
reported to be dramatically and progressively decreased in
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the peripheral blood of ALS patients, and these perturba-
tions significantly correlated with disease progression and
survival.12–16 In particular, at early disease stages, blood
CD25þFOXP3þTregs increase in number. This is perceived
as an initial protective mechanism to suppress inflamma-
tion, whilst, as disease progresses, this attempted compen-
satory mechanism fails and Treg counts gradually and
significantly decrease. Specifically, a shift from protective
Tregs/T-helper(Th)2 and anti-inflammatory (M2) microglia
phenotype to the pro-inflammatory Th1/Th17 and M1
microglia has been reported.17–20 Furthermore, ALS Tregs
were functionally impaired and less effective at promoting
immune-suppression.14,16,21 However, evidence of pharma-
cological restoration of Treg immune-modulatory functions
by in vitro culturing in the presence of interleukin (IL)-2
and rapamycin was reported.21 Additionally, studies
involving ALS mouse models showed that either the pas-
sive transfer of endogenous Tregs18 or intraperitoneal
injection of rapamycin and IL-2c (IL-2 together with its
monoclonal antibody)16 can efficiently expand the Treg
count and prolong survival.
IL-2 is crucial for the differentiation, function and survival
of Treg cells.22,23 In particular, low-dose IL-2 (ld-IL-2) has
been shown to be safe and to promote significant Treg ex-
pansion in healthy volunteers included in a phase I clinical
trial24 as well as in phase I/II25–29 or II30,31 studies involv-
ing patients suffering from several autoimmune disorders.
Given this background, ld-IL-2 was proposed as an
immune-modulatory treatment for ALS. A randomized,
placebo-controlled pilot phase-II clinical trial, Immuno-
Modulation in Amyotrophic Lateral Sclerosis (IMODALS)
was carried out to understand the safety and activity of ld-
IL-2 in ALS patients. Thirty-six participants were recruited
and randomly divided into three treatment arms: placebo,
1MIU and 2MIU IL-2. Ld-IL-2 appeared to be safe and
well tolerated, with no serious adverse events reported.32
In this report, we examined the gene expression
changes that occurred in the IMODALS cohort. In par-
ticular, the leukocyte population from participants has
been transcriptionally profiled to assess differences in the
response to the two treatment doses and to determine the
longitudinal profile of gene expression changes through-
out the trial. Consistent with the study of Camu et al.,
we found a dose-dependent and time-dependent upregula-
tion of Treg-specific transcripts. Moreover, a downregula-
tion of inflammatory-related pathways was evident in
response to IL-2 administration. Finally, a regression
model was generated to stratify participants and to pre-
dict the Treg-response to ld-IL-2 in patients with ALS.
Materials and methods
Trial design
IMODALS (NCT02059759) is a randomized, placebo-
controlled phase-IIa clinical trial (Ethical approval
number¼ 2014,09,01-ter). Thirty-six participants between
18 and 75 years of age were recruited and randomly
assigned to one of three treatment arms: 1 million
International Units (MIU) or 2MIU-IL-2 (Human recom-
binant IL-2 also known as aldesleukin or with the
commercial name ProleukinV
R
, Novartis. This will be sub-
sequently referred to in the text as ld-IL-2) or placebo
(5% glucose solution) as previously described.32
Participant characteristics are summarized in Table 1.
Briefly, patients received subcutaneous injections once
daily for 5 days every 28 days for a total of three admin-
istration cycles. For the purpose of transcriptomic profil-
ing, blood was taken at four timepoints: day(D)1 or
baseline; D8 - three days after the first injection cycle;
D64 - three days after the last treatment cycle; and D85
- 24 days after the last treatment.
Blood collection, processing and
RNA extraction
Blood samples were collected at each study visit.
LeukoLOCKTM filters (AmbionTM) allowed white blood
cell isolation and cells were stabilized in RNAlater
(Thermofisher Scientific). Samples were stored at –80C
and shipped in dry ice to the Sheffield Institute for
Translational Neuroscience (SITraN). Total RNA was
extracted using LeukoLOCKTM Total RNA isolation kit
(AmbionTM) according to the manufacturer’s instructions.
RNA quantity and quality were assessed using Nanodrop
ND-1000 (Thermo Scientific) and Agilent 2100 Bioanalyser
(Agilent Technologies), respectively.
Microarray preparation,
normalization and quality control
Affymetrix ClariomD human microarrays (Applied
BiosystemTM) were produced from white blood cell total
RNA (200ng of RNA with RNA integrity number> 8) as
per manufacturer’s instructions (GeneChipTM WT PLUS
Reagent Kit, Applied Biosystems and GeneChipTM hybrid-
ization, Wash and Stain Kit, Applied Biosystems). A total
of 107 microarrays were generated: 24 arrays form sam-
ples at D1 (12 placebo and 12 2MIU-IL-2-treated
patients), 23 from D8 (12 placebo and 11 2MIU-IL-2), 36
from D64 (12 placebo, 12 1MIU and 12 2MIU-IL-2) and
24 from D85 (12 placebo and 12 2MIU-IL-2). One sample
from D8, C01P011 failed RNA quality control (QC) and
was therefore excluded from the analysis. Microarrays
were normalized using the signal space transformation ro-
bust multi-chip analysis method. Expression ConsoleTM
(Affymetrix) software was used to perform QC. All 107
microarrays passed QC and were used for downstream
analysis.










































































Microarray data from D64 were analysed using
Transcriptome Analysis Console 4.0 (Affymetrix) to iden-
tify differential expression between placebo, 1MIU-IL-2
and 2MIU-IL-2 treated patients. Gene-level analyses were
performed and RefSeq annotations were used for enrich-
ment analyses.
To accomplish complex multifactorial-designed expres-
sion analyses, the R package Limma was used.33 A
RefSeq filtering was applied before launching the analy-
ses. Three differential expression tests were performed in
which treated patient transcriptomes at specific time
points (D8, D64 and D85) were compared to baseline
levels (D1) and normalised to the same comparison with-
in the placebo group. These analyses are referred to as:
DD8; DD64; DD85 . Owing to samples being processed
at different times, two batches were recognizable in our
data. For this reason, data were adjusted for batch effects
including batch identifiers as variables within the Limma
statistical model.33,34
Gene enrichment and pathway
analysis
Lists of differentially expressed genes (DEGs), previously
obtained from either TAC or Limma, were inputted into
Enrichr35,36 to enrich for Gene Ontology Biological
Process (GO BP). Long lists of altered GO BPs were pro-
duced with often redundant terms. To allow an easier in-
terpretation of data, the software reduce and visualize
gene ontology (REVIGO) was used. This grouped GO
terms into clusters depending on their semantic similarity
(cut-off ¼ 0.5). A GO process was then chosen as a clus-
ter representative to recapitulate similar terms.37 Finally,
Table 1 Patient characteristics and response type.
Patient ID Gender Treatment type Age at D1 Disease decline per month Treg count at D64 2MIU-treated
response
classification
C01P001 Male 1MIU-IL-2 40.2 0.114 115.14 –
C01P005 Male 1MIU-IL-2 42.5 0.514 145.97 –
C01P008 Female 1MIU-IL-2 47.7 0.400 120.59 –
C01P010 Female 1MIU-IL-2 65.4 0.378 151.50 –
C01P013 Male 1MIU-IL-2 44.7 0.643 114.18 –
C01P020 Female 1MIU-IL-2 46.4 0.296 160.49 –
C01P023 Male 1MIU-IL-2 53.8 0.075 87.79 –
C01P024 Female 1MIU-IL-2 55.8 0.600 156.26 –
C01P027 Male 1MIU-IL-2 64.4 0.800 154.40 –
C01P033 Male 1MIU-IL-2 59.1 0.250 91.62 –
C01P035 Female 1MIU-IL-2 75.4 0.424 146.48 –
C01P038 Male 1MIU-IL-2 64.4 0.224 81.65 –
C01P003 Male 2MIU-IL-2 36.5 1.000 406.72 High
C01P004 Female 2MIU-IL-2 47.3 0.688 169.13 Moderate
C01P009 Female 2MIU-IL-2 68.8 0.692 434.47 High
C01P011 Male 2MIU-IL-2 76.6 1.500 144.34 Low
C01P016 Male 2MIU-IL-2 63.4 0.375 88.99 Low
C01P018 Male 2MIU-IL-2 59.8 0.444 117.88 Low
C01P021 Female 2MIU-IL-2 62.7 0.226 505.70 High
C01P026 Male 2MIU-IL-2 72.5 0.417 222.66 Moderate
C01P028 Male 2MIU-IL-2 63.4 0.148 176.08 Moderate
C01P032 Male 2MIU-IL-2 44.4 0.667 181.13 Moderate
C01P036 Male 2MIU-IL-2 56.5 0.209 52.22 Low
C01P037 Male 2MIU-IL-2 40.3 1.375 263.93 High
C01P002 Male Placebo 47.5 0.375 30.08 –
C01P006 Male Placebo 44.2 0.277 34.22 –
C01P007 Male Placebo 49.2 0.351 55.14 –
C01P012 Female Placebo 64.6 0.455 35.41 –
C01P014 Male Placebo 52.6 0.350 90.37 –
C01P017 Male Placebo 42.2 0.143 60.33 –
C01P022 Male Placebo 63.6 0.429 32.99 –
C01P025 Male Placebo 61.7 0.909 84.88 –
C01P030 Male Placebo 58.5 0.313 25.63 –
C01P031 Male Placebo 53.9 1.600 46.73 –
C01P034 Female Placebo 69.7 0.579 57.52 –
C01P039 Female Placebo 69.7 0.241 32.49 –
This table illustrates the gender, age, disease decline per month and treatment regimen of each participant. Moreover, Treg count at D64 is displayed and these data have been used to
classify the patient response to 2MIU-IL-2 (high responders: Treg level at D64> 250 cells/ml; moderate responders: between 150 and 250 cells/ml; low responders:< 150 cells/ml).














































































Inc.) and the Ingenuity Knowledge Base to retrieve signifi-
cantly altered pathways in a data set allowing predictions
of their activation/inhibition through the calculation of z-
scores (activation: z-score > 0, inhibition: z-score < 0).38
DEG lists from the Limma comparisons DD8 and DD64
were submitted to IPA and analysed. Plots were gener-
ated using ggplot2 v3.2.2, gplots v3.1.1 or treemap
v2.4.2 R libraries.
Quantitative real-time PCR
Quantitative real-time polymerase chain reaction (qRT-PCR)
was performed for microarray data validation. Four key
Treg transcripts were selected: FOXP3 (Hs.PT.58.3671186),
IL2RA (Hs.PT.58.2187899), CTLA4 (Hs.PT.58.3907580)
and IKZF2 (Hs.PT.58.2960172) (Integrated DNA
Technologies Inc.). GAPDH (Hs.PT.39a.22214836) was
used as a reference gene as, from microarray data, its ex-
pression was stable across all time points, with no varia-
tions amongst patient groups. All the 2MIU-IL-2 and
placebo patient samples from the four time points were
screened. Three technical replicates were completed for each
condition.
200ng of total RNA were retrotranscribed to cDNA
using 5 qScriptTM DNA Supermix (Quantobio) by incu-
bating samples at 25C for 5min, at 42C for 30min and




DNA Technologies Inc.) and 2 LunaV
R
Universal qPCR
Master Mix (New England BioLabsV
R
Inc.). The mixture
was incubated at 95C for 3min and 40 cycles of amplifi-
cation at 95C for 10 s and 60C for 30 s were performed
using C1000 TouchTM Thermal cycler (Bio-Rad). Raw Ct
values were retrieved using CFX MaestroTM software (Bio-
Rad). DCt, DDCt and relative concentration (R) values
were computed as follows:
DCt ¼ Ct gene of interest – Ct reference gene
DDCT ¼ DCT – ðaverage DCT placebo sampleÞ
R ¼ 2DDCt:
NanoString
Samples from four high (Treg level at D64> 250 cell/ml
blood), four low-Treg-responders (Treg level at D64< 150
cell/ml) and four placebo patients at D1, D8 and D64
were investigated using the NanoString platform. Patient
classification is illustrated in Table 1. Briefly, 300ng of
total RNA was mixed with capture and reporter probes
from the auto-immune discovery panel. A hybridization




Technologies Inc.). The autoimmune discovery panel con-
tains 755 mRNA targets: 740 immune-related transcripts
and 15 housekeeping genes. NanoString data were ana-
lysed using nSolverTM4.0 and nCounter Advanced Analysis
2.0 (NanoString Technologies Inc.). Moreover, to identify
which selection of transcripts were responsible for patient
group differences, data were imported into Qlucore Omics
Explorer (Qlucore) and multigroup comparison statistical
analysis was performed.
Multiple linear regression model
To identify predictive biomarkers of the outcome of the
disease, each patient’s baseline expression of genes
included in the nanoString panel were correlated to their
Treg level at D64 (flow cytometry data).32 Pearson’s cor-
relation tests were performed with associate t-test statis-
tics. Six biomarker candidates—SBNO2, BTLA, CD27,
TRAF2, BLNK, TLR9—were selected. Given that
nanoString experiments were conducted only on a selec-
tion of patients, qRT-PCRs were performed in order to
obtain data at D1 from all 12 2MIU-IL-2 treated patients
and on three placebo samples as controls. qRT-PCR anal-
yses were carried out as previously described and the fol-
lowing primers were used: SBNO2 (Hs.PT.58.14833003),
BTLA (Hs.PT.58.20005939), CD27 (Hs.PT56a.2744
1991), TRAF2 (Hs.PT.583116982), BLNK (Hs.PT.58.
1645191), TLR9 (Hs.PT.58.40576968) (Integrated DNA
Technologies Inc.). Their averaged expression values from
three replicates were correlated (Pearson’s correlation) with
their associated Treg counts at D64. Two transcripts—
TLR9 and CD27—were selected and a multiple linear re-
gression model was generated using the R lm() function.
Scatterplot3d package in R was used for 3D-plot gener-
ation. Finally, to test our model, a leave-one-out cross-valid-
ation (LOOCV) was performed using the package caret
v6.0.86.
Statistical analysis
Differential expression analysis was performed using TAC
and Limma which use F-test and Empirical Bayes statis-
tics to retrieve significant DEGs. In both cases, P-value
(<0.05) and fold change (1.2  FC  1.2) cut-offs
were applied. Fisher’s exact test was used for gene enrich-
ment by Enrichr and IPA (P-value< 0.05). To identify
statistical differences between sample groups in qRT-PCR
data, a two-way ANOVA analysis with either Tukey’s or
Sidak’s correction for multiple comparisons was per-
formed when analysing differences between treatment
types at a single time or across different time points with-
in the same administration regimen, respectively.
Significant (P< 0.05) differentially expressed nanoString
transcripts were assessed using Qlucore’s multigroup com-
parison statistical analysis. Finally, the caret package in R









































































was used for regression model statistics (lm() function,
P< 0.05) and LOOCV.
Data availability statement
Data supporting these study findings is available from the
corresponding author, upon reasonable request. Array




Differences in patient response to the two IL-2 doses
were evaluated comparing participants’ gene expression
at D64, when the drug reaction was hypothesized to peak.
To this end, microarrays from 1MIU and 2MIU-treated
patients were compared to placebo (1MIU_vs_Placebo and
2MIU_vs_Placebo analyses) using TAC software.
Following treatment with 1MIU-IL-2, 3873 transcripts
(760 RefSeq-annotated) were significantly differentially
expressed (2097 decreased, 1776 increased). The
2MIU_vs_Placebo comparison identified 6352 significantly
differentially expressed transcripts (3530 decreased, 2822
increased), of which 1764 were RefSeq. Of importance,
1160 transcripts (375 RefSeq-annotated), were commonly
differentially expressed (Fig. 1A).
To investigate the biological functions of the DEGs,
gene ontology analyses were performed importing
RefSeq lists into Enrichr. Sixty-two GO biological
processes (BPs) were found to be significantly enriched
in the unique list of DEGs characteristic of
1MIU_vs_Placebo, which were summarized into 27 clus-
ters using REVIGO. In contrast, transcripts exclusively
differentially expressed in 2MIU_vs_Placebo comparison
were enriched in 129 GO BPs which formed 35
REVIGO clusters. Only a few immune-related processes
were identified amongst 1MIU_vs_placebo unique list,
whereas, evidence of immune-modulation (including
regulation of T and B-cell receptors and regulation of
antigen receptor mediated signalling) was identified
amongst the 2MIU_vs_placebo-exclusive list (Fig. 1A
and Supplementary Fig. 1). Importantly, 138 GO BPs
were significantly enriched from the list of commonly
DEGs in both comparisons (summarised in 26 REVIGO
clusters). Interestingly, the large majority of these clus-
ters were involved in immune-modulation: an extensive
T-cell-subset regulation was reported together with
modulation of production and secretion of multiple
cytokines (Supplementary Fig. 1). This suggested that
both doses were possibly able to promote Treg expan-
sion and/or activation. Interestingly, transcripts involved
in ganglioside and lipid metabolism were also reported
as commonly altered (upregulated) following the admin-
istration of both ld-IL-2 doses (Supplementary Fig. 1).
To investigate potential differences in the magnitude of
Treg activation, FCs from the two comparisons
(1MIU_vs_Placebo and 2MIU_vs_Placebo) were com-
pared. A dose-dependent reaction was found for 260 out
of 375 (69.3%) RefSeq common DEGs: increased tran-
scripts showed a greater level of upregulation, and simi-
larly, decreased DEGs were more downregulated
following the higher dose administration of IL-2 (Fig.
1B). Consistently with this, the expression of four key
Treg activation markers (FOXP3, CTLA4, IKZF2,
IL2RA) showed a dose-proportional upregulation (Fig.
1C). Given the greater degree of immune-regulation pro-
moted by 2MIU-IL-2, we focussed on this higher-dose
treatment for further analyses.
Gene expression changes during
2MIU-IL-2 treatment
Patients’ transcriptomic differences between treatment and
placebo groups throughout the administration period
were assessed from the microarray data using Limma.
Two comparisons, DD8 and DD64, identified specific
2MIU-IL2-mediated changes at D8 and 64 compared to
baseline and normalized to the placebo group.
The comparison DD8 identified 2635 RefSeq genes as
significantly differentially expressed (1953 decreased, 682
increased), while only 525 RefSeq genes (198 decreased,
327 increased) resulted from DD64 (Fig. 2A and B). A
widespread decrease in gene expression was reported
after the first treatment cycle, while this effect seemed to
be no longer present at later time points. In contrast, at
D64 a more pronounced upregulation of gene expression
was documented. Interestingly, in both comparisons, one
of the most significant DEG is FOXP3 which suggests an
activation of Tregs starting from the first cycle and con-
tinuing throughout the administration period.
To understand the biological functions exerted by the
identified DEGs, upregulated and downregulated lists of
transcripts from the two comparisons were imported sep-
arately into Enrichr and GO analysis was conducted. The
DD8 comparison revealed 448 downregulated GO BPs
while DD64 showed only 35 downregulated significantly
enriched terms. In contrast, analysis of upregulated DEGs
identified 35 significantly enriched GO BPs in DD64 com-
parison while, only 10 processes were observed in DD8.
The most significant DD8 GO BPs revealed alterations
(both increase and decrease) in different processes
involved in RNA metabolism at D8. These included var-
iations in both non-coding RNA and mRNA processing,
splicing and gene expression regulation (Fig. 3A and B).
Moreover, evidence of inflammatory suppression was also
documented, with neutrophil activation and degranulation
being significantly decreased. In contrast, the top 10 sig-
nificant GO BPs from DD64 did not show a clear inflam-
matory process downregulation, while inhibition of other
mechanisms including iron transport and lipid processing
were observed. However, several immune-regulatory









































































Figure 1 End of the treatment (D64) analysis and dose-dependency. (A) Venn diagram showing significant (P-value <0.05)
differentially expressed genes (DEGs) from either 1MIU_vs_Placebo or 2MIU_vs_Placebo TAC (Transcriptome analysis console)
comparisons. All altered transcripts are reported in brackets while RefSeq annotated transcripts are shown in bold. Overlapping common
DEGs are also shown. For each RefSeq transcript list shown in the Venn diagram, the top 10 significant enriched Gene Ontology (GO)
biological processes are plotted. X-axis: Log10 (enrichment P-value); y-axis: GO term. (B) Scatter plot displaying 375 RefSeq DEGs altered in
common within the two treatment groups and their fold changes resulting from either 1MIU_vs_Placebo (X-axis) or 2MIU_vs_Placebo (Y-
axis) comparisons. 260 out of 375 genes (69.3%) show a dose-dependent expression (in blue) while transcripts showing no dose-dependent
trend are represented in red. (C) The expression levels (SST-RMA normalized log2 of signal intensity from the microarrays) of 4 Treg
activation markers—FOXP3, CTLA4, IKZF2 and IL2RA—are shown. A significant dose-dependent upregulation of these transcripts is detected.
Box plots show mean 6 SD. A two-way ANOVA with Tukey’s correction for multiple comparisons was conducted. *: Adjusted P-value
< 0.05, **: Adjusted P-value< 0.01, ***: Adjusted P-value< 0.001, ****: Adjusted P-value< 0.0001. SST-RMA, signal space transformation
robust multi-chip analysis method for microarray data normalization.









































































processes, especially those involved in Treg-activation and
differentiation were upregulated at D64. Interestingly,
enrichment in muscle regulatory process was also docu-
mented (Fig. 3C and D).
Pathway alteration during 2MIU-IL-
2 treatment
The lists of significant DEGs (P-value< 0.05 and 1.2 
FC  –1.2) outputted from DD8 and DD64 were
imported into IPA to identify pathways altered longitu-
dinally through the trial.
Seventy-seven pathways were altered in DD8, the top
twenty significant processes are displayed in Fig. 4A
while the complete list is available in Supplementary
Table 1. An inhibition of inflammatory mechanisms was
identified, with functions of both innate (phagocytic cells,
neutrophils, eosinophils, macrophages/monocytes and
natural killers) and adaptive immune cells (cytotoxic T
lymphocytes and B cells) being decreased. Moreover, in-
hibition of NF-kB and signalling related to several cyto-
kines were documented. Interestingly, negative regulation
of pathways subserving autoimmune diseases, such as
multiple sclerosis and systemic lupus erythematosus, were
also found. Taken together, these results suggest a
broader suppression of inflammatory processes, which are
known to be activated in ALS, and also involved in other
autoimmune pathologies. Additionally, the NRF2-medi-
ated oxidative stress response pathway was decreased at
D8 suggesting a reduction in oxidative stress. Moreover,
two processes involved in CNS homeostasis, neuregulin
and glioma signalling pathways, were inhibited.
Only 16 pathways were altered in DD64 (Fig. 4B and
Supplementary Table 2). The majority of these were
involved in the metabolism of several molecules, including
amino acids and sulphate-containing compounds.
Figure 2 Transcriptional changes during 2MIU-IL2 administration. Volcano plots displaying differentially expressed genes
(DEGs) resulting from the comparisons DD8 (A) and DD64 (B). DEGs are plotted and colour-coded depending on their fold change
(FC) and their significance levels (Log10 P-value): non-significant or transcripts that failed the FC cut-off are reported in grey, significant and
with FC 1.2 in blue and significant and with FC 1.2 in red. Three black lines are also shown: the horizontal line indicates the significance
threshold (Log10 P-value¼ 1.3) and two vertical dotted lines mark the FC cut-off at 1.2 and 1.2, respectively. A widespread
downregulation is detectable at D8, while at D64 an increased upregulation is reported amongst which some Treg makers are recognizable
(Empirical Bayesian statistics was conducted using Limma to find significant DEGs).









































































However, two mechanisms implicated in T-cell subset
modulation were altered. In particular, activation of the
Th2 pathway was observed. Importantly, Th2 cells share
some anti-inflammatory properties with Tregs mediated
by IL-4 secretion.18,19 These findings suggest an activa-
tion of immune-modulatory processes at the later trial
stages. This is further confirmed by our data showing an
increased expression of key mediators of Treg develop-
ment, activation and functions following the last injection
cycle compared to the first (Fig. 4C).
IPA diseases and functions’ analysis revealed an al-
most opposite pathway regulation occurring at D8 and
D64. In fact, while the vast majority of the pathways
showed negative z-scores, which indicates inhibition,
after the first cycle, a trend towards inversion was vis-
ible later on with a positive z-score-skewed phenotype
(Supplementary Figs. 2 and 3). This analysis reinforces
previous observations indicating a rapid inhibition of
inflammatory mechanisms after the first cycle. In fact,
we have shown a repression of pathways involved in
Figure 3 Altered biological processes during 2MIU-IL2 administration. Bar plots resulting from GO Biological Processes
(GO BP) enrichment analysis. In particular, the top 10 significant downregulated (A) and upregulated (B) GO BPs from DD8 and
top 10 significant downregulated (C) and upregulated (D) GO BPs from DD64 are shown. Significance threshold lines are reported in black
(Log10 P-value¼ 1.3). A significant downregulation of pro-inflammatory processes involving neutrophils and an alteration in the RNA
metabolism are observed at D8 while, later during the course of the trial, a significant upregulation of Treg processes is documented (Fisher’s
exact statistical test was performed using Enrichr to cluster transcripts into GO BP terms).









































































Figure 4 Ingenuity Pathway Analysis (IPA). Bar plots displaying top 20 significant IPA canonical pathways. Activated
(z-score>0, in orange) or inhibited pathways (z-score<0, in blue) resulting from the analysis DD8 (A) and DD64 (B) are
shown. Significant pathways but with z-score equal to 0 (in white) or with no activation prediction available in the software (in grey) are also
reported. A significance threshold line is displayed in orange (Log10 P-value¼ 1.3). A widespread downregulation of inflammatory pathways
is detectable at D8 while fewer pathways are altered at D64. However, activation of Th2 is reported (A right-tailed Fisher’s Exact test was
conducted to calculate significantly altered pathways and the z-score was computed to predict the activation state of each mechanism).
(C) Customized pathways created with IPA displaying key regulators of activation, development and functions of Tregs. In particular, two
pathway maps displaying fold changes (FCs) from DD8 and DD64 are juxtaposed for comparison. Significant (P-value< 0.05) differentially
expressed genes are shown in bold and their gene symbol is underlined. A more prominent upregulation of Treg genes is reported at D64.
Data were analysed through the use of IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis).









































































diapedesis of leukocytes—including phagocytes, mono-
cytes, granulocytes and neutrophils—as well as develop-
mental and functional inhibition of these cells. Cell
death mechanisms were also found to be activated in
leukocytes (Supplementary Fig. 2 and Supplementary
Table 3). This may indicate a reorganization within im-
mune cells happening at this time point. Concomitantly,
downregulation of cell death processes in neurons and
brain cells (‘cell death of brain’, ‘cell death of brain
cells’, ‘apoptosis of cortical neurons’) was observed, to-
gether with a mild activation of the pro-survival ‘protec-
tion of cortical neurons’ which is particularly interesting
in the context of ALS (Supplementary Fig. 2 and
Supplementary Table 3). Furthermore, processes
involved in metabolism, synthesis and production of re-
active oxygen species (ROS) were inhibited at this time
point.
In contrast, DD64 analysis revealed an extensive activa-
tion of regulatory processes (‘regulation of cells’, ‘sup-
pression of lymphocytes’, ‘differentiation of induced
Tregs’, ‘regulation of mononuclear leukocytes’ and ‘acti-
vation of Tregs’) and concomitant activation of leukocyte
apoptosis (Supplementary Fig. 3). This suggested a more
evident expansion of protective Tregs following the third
cycle. However, unlike D8, processes involved in immune
cell movement and recruitment seemed to increase at this
time point. The reported activation of the ‘inflammatory
response’ process may be perceived as counter intuitive.
However, when investigating the transcripts involved in
this process by the software, it was clear that several
anti-inflammatory agents (such as FOXP3, IDO1,
IL2RA) were also included and thus ‘inflammatory re-
sponse’ included both pro and anti-inflammatory modu-
lators (Supplementary Table 4).
Gene expression changes after
2MIU-IL-2 treatment
Subsequently, we analysed the transcriptional changes
which occurred in IMODALS patients during the follow-
up period to investigate whether the ld-IL-2 effect was
sustained once treatment ceased. Limma was used to per-
form DD85 comparison. We found 508 RefSeq tran-
scripts to be significantly differentially expressed (281
upregulated, 227 downregulated) (Fig. 5A). Interestingly,
four main Treg activation markers—FOXP3, IL2RA,
CTLA4, IKZF2—were no longer significantly differential-
ly expressed. The comparison of their FC from DD85
with the results retrieved from the previous analyses dur-
ing drug administration -DD8 and DD64- showed that
the expression of Treg markers progressively increased
during the administration cycles, but it dramatically
decreased once treatment ceased (Fig. 5B). This suggested
that 2MIU-IL-2-promoted Treg activation was no longer
preserved at D85. Furthermore, to investigate the bio-
logical functions of the upregulated and downregulated
DEGs, a GO analysis was carried out. Twenty-five
upregulated and 23 downregulated significantly enriched
GO BPs were found and none of these were related to
immunological processes (Supplementary Fig. 4A and B).
Interestingly though, an upregulation in mechanisms
involved in CNS development, including neural tube de-
velopment and neuronal differentiation, were observed,
while downregulation of neurotransmitter transport and
axonogenesis was documented.
Microarray validation and variability
in patient response
Microarray data validation was performed through
qRT-PCR. Four key Treg markers (FOXP3, IL2RA,
CTLA4, IKZF2) were chosen and samples from all
2MIU-IL-2-treated and placebo patients across all time
points were screened. In line with microarray data,
qRT-PCRs showed a time-dependent increase in the
mRNA levels of these markers during the administration
period which peaked at D64 (Fig. 6A). At D85 this
upregulation was no longer sustained and transcripts
showed levels more comparable to baseline. In contrast,
no significant alterations were reported longitudinally
within the placebo group. A considerable variability in
the expression of Treg markers was registered amongst
2MIU-IL-2-treated patients. This suggested the existence
of inter-individual variations in the response of ALS
patients to the drug. This finding is in line with flow-
cytometry data (Fig. 6B and previously published
data32) showing a wide range of Treg count increases
during the administration period (standard deviation of
Treg cells measured at D8¼ 101.7 and at D64¼ 144.8).
Given these results, we classified our 2MIU-IL-2-treated
patients as low, moderate and high-Treg-responders
according to their Treg levels registered at D64 (high ¼
Treg level at D64> 250 cell/ml; moderate ¼ Treg level
between 250 and 150 cell/ml; low ¼ Treg level at
D64< 150 cell/ml; see Table 1). Importantly, no signifi-
cant differences in age or in disease decline per month
were reported amongst the three subgroups at baseline
(One-way ANOVA with Tukey’s correction).
To further investigate these inter-individual dissimilar-
ities and to evaluate the existence of key transcriptional
patterns underlying the different magnitude of Treg ex-
pansion in low and high-Treg-responders, nanoString
analyses were performed. In particular, we aimed to find
immunological transcript dissimilarities in these partici-
pants across the administration period (D1, D8 and D64)
and, for this reason, the nanoString autoimmune discov-
ery panel was used. We performed a principal component
analysis (PCA) analysis to visualize transcriptional-driven
group separation (Fig. 6C). High-Treg-responder samples
from D8 and D64 appeared to be spatially distanced,
whereas, placebo and low-Treg-responders were more
dispersed and partially overlapped. Interestingly, low at
D64 and high-Treg-responders at D1 were overlapping
(Fig. 6C). We then identified a cluster of 81









































































discriminatory transcripts that were responsible for this
PCA spatial separation (Fig. 6D). This included genes
encoding both pro- and anti-inflammatory agents. At
baseline, an almost opposite trend was reported between
high and low-Treg-responders in this selected panel of
transcripts.
Lastly, pathway scoring analysis was performed. A
sharp downregulation of pro-inflammatory pathways was
reported in both high and low 2MIU-IL-2 Treg-respond-
ers (Fig. 7). However, baseline scores were considerably
different between these two groups. Collectively, these
results suggested that an almost opposite immunological
phenotype characterized high and low-Treg-responders
prior to drug administration. Therefore, this might have
significantly influenced the participant reaction to 2MIU-
IL-2.
Predictive biomarker identification
Given the inter-individual differences observed, we aimed
to identify transcripts whose expression at D1 could pre-
dict 2MIU-IL-2-mediated Treg-response. In particular, we
aimed to identify biomarkers of gene expression that
could predict target engagement at the end of the trial
(expressed as Tregs count at D64). To this end, we con-
ducted a preliminary screening by correlating the expres-
sion of all the transcripts included in the autoimmune
nanoString panel at D1 with Treg levels registered at
Figure 5 Transcriptional changes during the follow-up period. (A) Volcano plot showing differentially expressed genes (DEGs)
resulting from the comparisons DD85. DEGs are plotted and colour-coded depending on their fold change (FC) and their significance levels
(Log10 P-value): non-significant transcripts or transcripts that failed the FC cut-off are reported in grey, significant and with FC 1.2 in
blue and significant and with FC 1.2 in red. Three black lines are also shown: the horizontal line indicates the significance threshold
(Log10 P-value¼ 1.3 or P-value¼ 0.05) and the two vertical dotted lines mark the FC cut-offs at 1.2 and 1.2, respectively (Empirical
Bayesian statistics was conducted using Limma to find significant DEGs). (B) Plot displaying the variation in the expression of four key Treg
activation markers—FOXP3, IL2RA, CTLA4 and IKZF2—throughout and after the administration period. Their expression increases during the
2MIU-IL-2 treatment and peaks at D64 but the levels of expression decrease at D85. On the x-axis the different Limma comparisons are
shown while on the y-axis the FC for each transcript is reported.









































































Figure 6 Microarray validation and patient variability. (A) Graphs showing expression of FOXP3, IL2RA, CTLA4 and IKZF2 in 2MIU-IL-2
treated (in red) and placebo (in blue) patients at the four different time points (D1, D8, D64 and D85). Data were generated through qRT-PCR. A
time-dependent activation of these markers is reported in the ld-IL-2 group. Box plots display mean 6 SD (technical replicates ¼ 3). A two-way
ANOVA with either Sidak (for comparisons between different treatment regimens, significant differences indicated with *) or Tukey (for
comparisons between time points within the same treatment type, significant differences indicated with #) correction for multiple comparisons









































































D64 or with the expression of IL2RA at D64. Thirty-five
genes showed expression levels at D1 which significantly
correlated with both the variables and six biomarker
candidates (TLR9, SBNO2, CD27, BLNK, TRAF2 and
BTLA) were selected which had the best correlation coef-
ficients and statistical significance (Supplementary Table
5). However, given that only high and low-Treg-respond-
ers were screened through nanoString, the expression of
these transcripts in all patients was investigated through
qRT-PCR.
TLR9 and CD27 were selected because their expression
at D1 showed the best correlation with Treg count at D64.
The rest of the proposed biomarkers instead did not signifi-
cantly correlate and for this reason were excluded from fur-
ther analyses (Supplementary Table 6). A strong negative
correlation was observed for TLR9 (R ¼ 0.809, R2 ¼
0.654, P-value¼ 0.0014) (Fig. 8A). A milder positive
correlation was reported for CD27 (R¼ 0.416, R2 ¼
0.173, P-value¼ 0.179) (Fig. 8B).
Expression data from TLR9 and CD27 at D1 were then
combined and used as variables to create a more robust
multiple linear regression model (Fig. 8C) which performed
better than single linear models and with metrics which
appeared encouraging (R2 ¼ 0.694, Adjusted_R2 ¼ 0.626,
P-value¼ 0.005). In particular, coefficient of determination
(R2) and fitting root mean squared error (RMSE) obtained
with this model were better than the values from TLR9
alone (R2multiple ¼ 0:694, RMSEmultiple ¼ 76.7,
R2TLR9 ¼ 0:654, RMSETLR9 ¼ 81.4).
Therefore, the computed multiple model formula
(Formula 1) could be used to predict ALS patient Treg
count after three 2MIU-IL-2 administration cycles once
the baseline level of CD27 and TLR9 expression is
known.
Formula 1 : Treg number D64
¼ 724:57þ 59:49 CD27ð Þ þ ð625:00 TLR9Þ
The model performance was assessed through LOOCV
and the emerging metric was computed (RMSE¼ 84.28).
Although this might be perceived as a high score, it needs
to be stressed that RMSE is a scale-dependent measure-
ment which means that it needs to be interpreted in the
context of the range of values assumed by the dependent
variable (Treg count at D64). As mentioned before, the
standard deviation for the Treg count was quite high
(SDTreg_D64¼ 144.8) and thus, if compared with the
LOOCV RMSE, we could conclude that the model was
sufficiently robust when predicting new sets of data.
Moreover, the predictive ability was also inspected
correlating experimentally measured, or observed Treg
counts at D64, with the predicted values (Fig. 8D). As
expected, a strong positive correlation was observed
(R¼ 0.833, P-value¼ 0.0007).
Discussion
Ld-IL-2 has been proposed as an immune-modulatory
strategy for ALS to promote Treg expansion, dampen
neuroinflammation and increase patient survival.39 A
pilot phase-II clinical trial was carried out to test the
safety and activity of 1MIU or 2MIU-IL-2.32 In the pre-
sent report, transcriptomic profiling of patient leukocytes
was performed to evaluate the effects of ld-IL-2 through-
out the IMODALS trial.
Firstly, we assessed whether the two ld-IL-2 doses
induced different reactions in IMODALS participants. To
this end, microarray expression data at D64 from all
treatment arms were compared. DEGs and GO enrich-
ment analyses revealed an immune-regulation, with T-cell
subset and the signalling related to several cytokines
being altered in both treatment arms. This suggested that
both doses efficiently promoted Treg expansion.
However, 2MIU-IL-2 induced a more pronounced im-
mune-regulation and a dose-dependent expression was
identified for the majority (70%) of the common DEGs.
This is in line with results reported by Camu et al. which
showed a dose-dependent increase in the percentage of
Tregs. Interestingly, ganglioside, ceramide and lipid me-
tabolism were commonly altered at the end of both
1MIU and 2MIU-IL-2 treatment regimens. These mecha-
nisms, especially ganglioside biosynthesis, have been
implicated in the pathogenesis of ALS.40 Thus, modula-
tion of these metabolic processes could potentially con-
tribute to the beneficial effects of ld-IL-2 on the
pathophysiology of ALS. Given the dose-dependency, fur-
ther analyses were conducted comparing only 2MIU-IL-2
with placebo participants.
Figure 6 Continued
was conducted. * or #: Adjusted P-value <0.05, ** or ##: Adjusted P-value <0.01. (B) Graph displaying the number of Tregs per ll of blood of
each 2MIU IL-2-treated participant at each time point (Flow-cytometry data). Patients are shown with different colours and their IDs are
reported in the legend (C) PCA plot summarizing expression differences between samples depending on treatment regimen and time point
(colour code legend is reported. H 2MIU D1, D8, D64 ¼ high-Treg-responders at D1, D8 and D64; L 2MIU D1, D8, D64 ¼ low-Treg-
responders at D1, D8 and D64 and Placebo at D1, D8 and D64). High-Treg-responders from D8 and D64 are the most different samples.
(Qlucore multi group comparison statistical test, P-value <0.05) (D) Hierarchically clustered heatmap displaying differences in the expression of
81 transcripts identified as discriminating variables from the PCA analysis in Fig. B. Gene expression variations across sample groups (H 2MIU
D1, D8, D64 ¼ high-Treg-responders at D1, D8 and D64; L 2MIU D1, D8, D64¼ low-Treg-responders at D1, D8 and D64 and Placebo at D1,
D8 and D64) are displayed as z-scores (positive z-scores in red, negative in blue). An opposite expression between high and low-Treg-
responders is detectable, especially at D1.









































































We then analysed our microarray data longitudinally.
A broad differential expression was observed in the com-
parison DD8. This can be interpreted as a rapid response
to the newly administered drug after the first treatment
cycle. Over the trial course though, an adaptation prob-
ably occurred and less DEGs were reported in DD64.
GO gene enrichment and IPAV
R
analyses were carried
out to identify pathways longitudinally altered throughout
the trial. An inhibition of inflammatory processes was
registered after the first administration cycle. In particu-
lar, transcripts associated with the function of both in-
nate (neutrophils, eosinophils, macrophages and natural
Figure 7 Pathway scoring analysis. Graph showing results from the pathway scoring analysis performed using Advanced Analysis nSolver
software. Pathway activation scores are plotted as a function of the different treatment type and time points (H 2MIU D1, D8, D64 ¼ high-
Treg-responders at D1, D8 and D64; L 2MIU D1, D8, D64 ¼ low-Treg-responders at D1, D8 and D64 and Placebo at D1, D8 and D64). An
evident downregulation of several inflammatory pathways is demonstrated in both high and low-Treg-responders although baseline
differences were observed between the two treated subgroups.









































































Figure 8 Biomarker identification analysis. Linear regression models describing the correlation between the expression of TLR9
(A) and CD27 (B) at the baseline (D1) and the Treg number at D64 for each 2MIU-IL-2 treated patient. Each dot represents a trial participant
(average expression values computed from 3 qRT-PCR experiments, N¼ 3) and they are colour-coded depending on their Treg-response
type: high (orange dots), moderate (yellow squares) and low (green triangles). A regression line (black) and its regression confidence bands
(grey) are also shown. Linear regression model for TLR9 (A: R ¼ 0.809, R2 ¼ 0.654, P-value¼ 0.0014) was stronger than the model for
CD27 (B: R¼ 0.416, R2¼ 0.173, P-value¼ 0.179) (C) Multiple linear regression analysis indicating the relationship between 2 predictors
(expression of TLR9 and CD27 at D1) and the response variable (number of Tregs at D64). A good prediction model was obtained
(R2 ¼ 0.6937and P-value ¼ 0.00487). Each dot represents a patient and they are colour-coded depending on their Treg-response type: high
(orange dots), moderate (yellow squares) and low (green triangles). The regression plane is also displayed in black. (D) Plot showing the
correlation between flow-cytometry-measured Treg counts (observed, X-axis) and Treg numbers predicted by our multiple linear model
(predicted, Y-axis). Correlation metrics (R¼ 0.833, R2 ¼ 0.693, P-value¼ 0.0007) suggest an acceptable predictive model. Each dot represents
a sample and a red dotted regression line is also shown.









































































killers) and adaptive immune cells (cytotoxic T-cells and
B-cells) were downregulated at D8. Of importance, evi-
dence of dysregulation in these immune system cells is
reported in the ALS literature. Neutrophil activation cor-
relates with disease severity and predicts patient sur-
vival.41–43 Peripheral blood natural killer alterations and
their infiltration into the spinal cord and motor cortex of
ALS patients has been reported.44,45 Although the role of
monocytes/macrophages in ALS is still to be elucidated,
recently, total CD14þ monocyte levels appeared signifi-
cantly higher, with increased M1 activation and pro-in-
flammatory features.17,46,47 Moreover, adaptive immune
system cells such as cytotoxic T-cells are known to infil-
trate the CNS and to contribute to the loss of motor
neurons.48,49
NF-kB, cytokine signalling pathways and pathways pro-
moting diapedesis of leukocytes were also down-regulated
after the first cycle and these may contribute to the ld-IL-
2-induced immune-suppression observed early after treat-
ment initiation. Leukocyte cell death mechanisms were
reported to be activated at this time point. However, this
process specificity towards leukocytes should be investi-
gated to exclude possible toxic effects on other cell types.
Concomitantly, pathway analysis showed evidence of
downregulation of cell death mechanisms in brain and
cortical neurons which may indicate a positive pro-survival
effect. Taken together, these data suggest that the initial
suppression of the immune system may have beneficial
effects by dampening the widespread inflammation charac-
teristic of ALS.
This seems to be a short-term effect given that the
downregulation of the majority of the inflammatory path-
ways was no longer present at D64. However, a robust
activation of immune-regulatory processes was observed
at this time point, with evidence of time-dependent acti-
vation of both Tregs and Th2 being observed. Of import-
ance, Th2 share anti-inflammatory and neuroprotective
properties with Tregs and both cell types are reduced in
ALS patients.18,19 Lymphocyte suppression and apoptosis
induction was recorded at D64 which might be due to
the inhibitory action of Treg/Th2 cells on inflammatory
mediators.
Alongside immunological pathway alterations, ld-IL-2
appeared to affect other biological mechanisms.
Metabolism, synthesis and production of ROS as well as
the NFR2-mediated oxidative stress response pathways
were inhibited at D8. Excessive ROS generation, oxidative
stress and consequently oxidative damage are key mecha-
nisms in the pathophysiology of ALS.50 NRF2 is a tran-
scription factor which promotes a cytoprotective response
including induction of anti-oxidant and anti-inflammatory
gene expression.51 Dysregulation in NRF2 signalling path-
ways has been reported in ALS and this is now considered
a promising therapeutic target.52,53 The observed NRF2
pathway inhibition may represent a detrimental short-term
effect of ld-IL-2 given that this suppression was not
detected at D64. However, considering the concurrent
downregulation of mechanisms involved in ROS produc-
tion, we can speculate that ld-IL-2 can instead have an
anti-oxidant effect by dampening the production of ROS
and therefore reducing the need for the NRF2-associated
stress response. However, further investigation is necessary
to verify this hypothesis.
Subsequently, we investigated the transcriptional pro-
files of IMODALS participants during the post-treatment
period. We found that the ld-IL-2 immune-regulatory ef-
fect was no longer preserved at D85 and the expression
of Treg markers was returning towards baseline levels.
These findings are consistent with those reported by
Camu et al. At the D85, GO enrichment analysis
revealed no significant alteration in immunological proc-
esses. However, some CNS developmental mechanisms
were upregulated (neural tube formation, development
and closure and positive regulation of neuron differenti-
ation) whereas processes involved in axonogenesis and
neurotransmitter transport were downregulated.
Microarray validation was also carried out through
qRT-PCR screening of four Treg markers. In line with
the microarray data, a time-dependent increase in the ex-
pression of all of these transcripts was observed within
the 2MIU-treated group whereas no significant changes
were observed in placebo participants. In particular, the
expression of Treg-specific markers peaked at D64, sug-
gesting the existence of a cumulative reaction to succes-
sive doses of 1d-IL-2. In line with microarray data, at
D85 these effects of 2MIU-IL-2 effect were no longer sus-
tained. This analysis also revealed inter-individual differ-
ences in terms of the patient response to ld-IL-2. This is
consistent with data presented by Camu et al and the sig-
nificant variability in terms of Treg expansion previously
reported in clinical trials evaluating ld-IL-2 in several
autoimmune disorders.26,28,31,54
Thus, the aim was to investigate the existence of dif-
ferences in participants’ gene expression that could re-
flect the observed variation in Treg expansion. For this
reason, patients were classified patients into high, mod-
erate and low-Treg-responders depending on their Treg
levels measured at D64. We then performed nanoString
experiments to characterize immunological transcription-
al differences between high and low-Treg-responding
participants. We successfully identified an 81 transcript
cluster which was able to discriminate between the two
different groups. This analysis revealed an almost oppos-
ite immune phenotype at baseline between high and
low-Treg-responders. Furthermore, pathway scoring analysis
revealed that a considerable amount of inflammatory path-
ways were progressively downregulated in both types of ld-
IL-2 Treg-responders. However, a more inflammatory-prone
phenotype seemed to characterize low-Treg-responders at
baseline. This might have exerted a significant influence on
their ability to mount a strong Treg-response to ld-IL-2.
Finally, we aimed to identify smaller sets of transcripts
capable of predicting the patient Treg-response to ld-IL-2.
To this end, the expression of all the genes included in









































































the nanoString panel at D1 was correlated with Treg lev-
els32 at D64. Two transcripts were selected: TLR9 which
showed a strong negative correlation and CD27 which
correlated positively with the D64 Treg count. Toll-like
receptors (TLR) are a class of pattern recognition recep-
tors implicated in pathogen identification and immune-re-
sponse initiation. Dysregulation of TLR9 signalling has
been associated with several autoimmune and neurodege-
nerative diseases.55,56 Interestingly, increased TLR9 ex-
pression was reported in the spinal cord of SOD1G93A
transgenic mice.57 CD27 is a member of the tumour ne-
crosis factor receptor family. The binding of its ligand,
CD70, leads to immune cell activation and a pro-inflam-
matory response. However, CD27-CD70 has key role in
Treg generation in the thymus and genetic ablation of
either protein leads to a reduced number of thymic
Tregs.58 Moreover, CD27-deficiency caused reduction in
Treg cell numbers.59,60 Interestingly, Zhao et al reported
CD27 as one of the downregulated transcripts solely dif-
ferentially expressed in the monocytes of rapidly progres-
sive ALS patients.61
TLR9 and CD27 expression data were then combined
and a robust multiple linear regression model with good
predictive capacity (R2 ¼ 0.694, Adjusted R2 ¼ 0.626,
P-value ¼ 0.005) was generated. Therefore, the model
formula should be able to forecast the magnitude of Treg
expansion in ALS patients after measuring the baseline
evels of TLR9 and CD27 expression. These can be consid-
ered as biomarkers of target engagement as their expres-
sion at recruitment is proposed to be predictive of cellular
target stimulation and therefore Treg expansion promoted
by three cycles of ld-IL-2. Importantly, if this pharmaco-
logical treatment provides evidence of clinical efficacy in
ALS patients in future phase II/III trials, our model may
be valuable for future precision medicine approaches, to
allow patient stratification and identification of the best
therapeutic strategy for each individual.
A limitation of our study is the small participant group
size, which particularly affects our analyses. In particular,
we recognize age and sex as crucial variables possibly
affecting ALS phenotype. However, in such a limited
sized cohort, we believe that stratifying for these factors
would have had a considerable impact in reducing the
statistical power of our analysis. Moreover, this limited
participant size also substantially affected our proposed
predictive biomarker research. However, preliminary eval-
uations are necessary to examine the safety and tolerabil-
ity of new proposed drugs. Further investigation is
needed to verify the immune-modulatory transcriptomic
effect of ld-IL-2 and to validate our predictive model. To
this end, a randomized, placebo-controlled, double-blind
phase-II clinical trial, MIROCALS (NCT03039673), is
currently active and aims to evaluate the effect of 2MIU-
IL-2 in a larger ALS cohort of 220 participants. This will
allow more complex examination of gene expression var-
iations throughout the trial and further investigation of
the variability in Treg-response as well as the validation
of the robustness of our proposed predictive model.
In conclusion, transcriptional profiling of leukocytes
from participants in the IMODALS trial revealed evidence
of immune modulation following ld-IL-2 administration.
Inter-individual differences in the treatment responses to
2MIU-IL-2 were observed and a two-biomarker-based
model able to predict drug-induced Treg-response was
identified. This could be particularly relevant in future
precision medicine approaches for ALS.
Supplementary material
Supplementary material is available at Brain
Communications online.
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